FDA generic-drugs chief resigns

03/14/2013 | Pharmalot.com

Dr. Greg Geba announced he will resign as director of the FDA's Office of Generic Drugs, just as the FDA has started collecting generic-drug manufacturer user fees. A planned reorganization of the office played a role in his decision, Geba said in a memo. Dr. Janet Woodcock, director of the Center for Drug Evaluation & Research, will temporarily cover Geba's duties.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA